No evidence yet of Singulair suicide risk

Published: Jan. 14, 2009 at 2:27 PM

WASHINGTON, Jan. 14 (UPI) -- The U.S. Food and Drug Administration said a safety review has yet to find conclusive evidence of any link between certain asthma drugs and suicide.

The agency last March announced that it was reviewing data that raised concerns about a possible association between the use of Singulair and behavior/mood changes, suicide, suicidal thinking and suicidal behavior.

The FDA has urged both healthcare professionals and patients to report side effects from the use of drugs Singulair, Accolate, Zyflo, and Zyflo CR to the FDA's MedWatch Adverse Event Reporting program.

The review was initiated by post-marketing reports of neuropsychiatric events associated with montelukast, zafirlukast and zileuton being reported to FDA's Adverse Event Reporting System.

The FDA said most of the reports of neuropsychiatric events are associated with montelukast -- marketed as Singulair -- currently the most commonly prescribed drug that acts through the leukotriene pathway.

© 2009 United Press International, Inc. All Rights Reserved.
Order reprints



Additional News Stories
CDC: Highest rate of smoking in W. Va. (2 min)
Climate change, California droughts linked (7 min)
Mortgage rates drop in week (8 min)
NASA to begin attempts to free Spirit (19 min)
UPI NewsTrack Entertainment News (20 min)
Mortgage activity up with rates mixed (20 min)
Atlanta coach, Washington players fined (32 min)
fark
Not news: ex-soldier finds a gun in his garden - Still not news: man hands gun into police - Fark:...
Bow wow wow, yippie yo, yippie yeah, Bow wow yippie yo yippie yeah (c)
Welcome to the internet, where men are men, women are men, and that 14 year old girl you're propositioning...
Using only a cell phone and a pelican, man turns his $2 Million Bugatti into a submarine
Unknown substance found on NJ Transit train. Probably cleanser
90% of students at City University of New York can't do basic algebra. So, you know...just like...